Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 9,050 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 9,050 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total transaction of $317,112.00. Following the completion of the sale, the insider directly owned 66,914 shares in the company, valued at $2,344,666.56. This trade represents a 11.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 0.5%

CSTL stock opened at $34.26 on Friday. The company’s 50 day simple moving average is $26.99 and its 200-day simple moving average is $25.42. The firm has a market capitalization of $1.05 billion, a PE ratio of -51.91 and a beta of 0.98. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85.

Get Castle Biosciences alerts:

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The firm had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Equities analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its position in shares of Castle Biosciences by 3,176.9% in the second quarter. California State Teachers Retirement System now owns 901,578 shares of the company’s stock valued at $21,503,000 after purchasing an additional 874,065 shares during the period. Empowered Funds LLC acquired a new position in Castle Biosciences in the second quarter valued at $3,395,000. Jefferies Financial Group Inc. purchased a new position in Castle Biosciences during the second quarter worth about $15,440,000. Bank of America Corp DE purchased a new position in Castle Biosciences during the second quarter worth about $2,355,000. Finally, Man Group plc acquired a new stake in Castle Biosciences in the 2nd quarter worth about $2,594,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

CSTL has been the subject of a number of analyst reports. Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a research note on Friday, May 29th. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Get Our Latest Analysis on CSTL

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.

Featured Articles

• Five stocks we like better than Castle Biosciences
• Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
• SEC Probe Puts Wall Street Leverage Risk Back in Focus
• A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
• Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.